| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
462.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
78,990 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$301,730 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
9 |
14 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2019-12-30 |
4 |
AS |
$19.49 |
$487,427 |
D/D |
(25,000) |
123,791 |
|
56% |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2019-12-30 |
4 |
OE |
$2.90 |
$72,500 |
D/D |
25,000 |
148,791 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-12-20 |
4 |
AS |
$20.17 |
$504,158 |
D/D |
(25,000) |
353,969 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-12-20 |
4 |
OE |
$2.70 |
$67,500 |
D/D |
25,000 |
378,969 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-12-19 |
4 |
AS |
$20.08 |
$501,898 |
D/D |
(25,000) |
353,969 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-12-19 |
4 |
OE |
$2.70 |
$67,500 |
D/D |
25,000 |
378,969 |
|
- |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2019-10-15 |
4 |
S |
$14.18 |
$87,891 |
D/D |
(6,200) |
66,758 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2019-10-15 |
4 |
S |
$14.24 |
$145,292 |
D/D |
(10,200) |
80,218 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2019-10-15 |
4 |
S |
$14.29 |
$168,593 |
D/D |
(11,800) |
123,791 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-10-15 |
4 |
S |
$14.44 |
$303,458 |
D/D |
(21,017) |
353,969 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2019-09-16 |
4 |
B |
$17.50 |
$15,000,003 |
I/I |
857,143 |
11,216,809 |
2.25 |
- |
|
| Nashat Amir |
Director |
– • – |
2019-08-01 |
4 |
AS |
$22.53 |
$695,392 |
I/I |
(30,866) |
11,034 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-31 |
4 |
AS |
$22.53 |
$701,674 |
I/I |
(31,139) |
11,333 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-30 |
4 |
AS |
$22.51 |
$2,029,560 |
I/I |
(90,175) |
11,635 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-29 |
4 |
AS |
$22.50 |
$7,403 |
I/I |
(329) |
12,508 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-26 |
4 |
AS |
$22.50 |
$626,153 |
I/I |
(27,829) |
12,511 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-24 |
4 |
AS |
$22.51 |
$447,098 |
I/I |
(19,866) |
12,781 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-23 |
4 |
AS |
$22.51 |
$1,396,053 |
I/I |
(62,033) |
12,973 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-22 |
4 |
AS |
$22.52 |
$1,097,019 |
I/I |
(48,704) |
13,574 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-19 |
4 |
AS |
$22.50 |
$23,693 |
I/I |
(1,053) |
14,046 |
|
- |
|
| Nashat Amir |
Director |
– • – |
2019-07-18 |
4 |
AS |
$22.50 |
$481,795 |
I/I |
(21,409) |
14,056 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2019-06-27 |
4 |
AS |
$20.21 |
$252,610 |
D/D |
(12,500) |
135,591 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2019-06-27 |
4 |
OE |
$2.90 |
$36,250 |
D/D |
12,500 |
148,091 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-05-24 |
4 |
GA |
$0.00 |
$0 |
D/D |
105 |
374,986 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2019-05-16 |
4 |
AS |
$18.46 |
$277,684 |
D/D |
(14,335) |
374,881 |
|
- |
|
297 Records found
|
|
Page 9 of 12 |
|
|
0.20 (5.41%) 
